Impact of BMI on the Survival of Renal Cell Carcinoma Patients Treated with Targeted Therapy: A Systematic Review and Meta-Analysis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi: 10.3322/caac.21551.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87. doi: 10.1016/j.ejca.2018.07.005.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernandez-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, et al. European Association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810. doi: 10.1016/j.eururo.2019.02.011.
   PubMed Web of Science ®Google Scholar
• Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, et al. Updated European Association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76(2):151–6. doi: 10.1016/j.eururo.2019.05.022.
   PubMed Web of Science ®Google Scholar
• Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193–205. doi: 10.1016/j.ctrv.2007.12.001.
   PubMed Web of Science ®Google Scholar
• Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res. 2006;12(24):7215–20. doi: 10.1158/1078-0432.CCR-06-2254.
   PubMed Web of Science ®Google Scholar
• Patard JJ, Rioux-Leclercq N, Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol. 2006;49(4):633–43. doi: 10.1016/j.eururo.2006.01.016.
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–34. doi: 10.1056/NEJMoa021491.
   PubMed Web of Science ®Google Scholar
• Bendtsen MAF, Grimm D, Bauer J, Wehland M, Wise P, Magnusson NE, Infanger M, Kruger M. Hypertension caused by lenvatinib and everolimus in the treatment of metastatic renal cell carcinoma. Int J Mol Sci. 2017;18(8):1736. doi: 10.3390/ijms18081736.
   Web of Science ®Google Scholar
• Kirkali Z. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. BJU Int. 2011;107(11):1722–32. doi: 10.1111/j.1464-410X.2010.09985.x.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol. 2011;59(4):526–40. doi: 10.1016/j.eururo.2011.01.002.
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12. doi: 10.1200/JCO.2007.15.6331.
   PubMed Web of Science ®Google Scholar
• Sharma R, Kadife E, Myers M, Kannourakis G, Prithviraj P, Ahmed N. Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. J Exp Clin Cancer Res. 2021;40(1):186. doi: 10.1186/s13046-021-01961-3.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Chang YC, Cheng TY, Lo K, Liu SJ, Yeh TL. The association between metabolically healthy obesity and risk of cancer: a systematic review and meta-analysis of prospective cohort studies. Obes Rev. 2020;21(10):e13049. doi: 10.1111/obr.13049.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95(3):727–48. doi: 10.1152/physrev.00030.2014.
   PubMed Web of Science ®Google Scholar
• Park YH, Moon HW, Cho HJ, Ha US, Hong SH, Lee JY, Kim SW, Han K, Ko SH. Cumulative obesity exposure increases the risk of kidney cancer: a longitudinal nationwide cohort study. Am J Cancer Res. 2021;11(10):5016–26.
   PubMed Web of Science ®Google Scholar
• Sanfilippo KM, McTigue KM, Fidler CJ, Neaton JD, Chang Y, Fried LF, Liu S, Kuller LH. Hypertension and obesity and the risk of kidney cancer in 2 large cohorts of US men and women. Hypertension. 2014;63(5):934–41. doi: 10.1161/HYPERTENSIONAHA.113.02953.
   PubMed Web of Science ®Google Scholar
• Li Y, Li C, Wu G, Yang W, Wang X, Duan L, Niu L, Chen J, Zhang Y, Zhou W, et al. The obesity paradox in patients with colorectal cancer: a systematic review and meta-analysis. Nutr Rev. 2022;80(7):1755–68. doi: 10.1093/nutrit/nuac005.
   PubMed Web of Science ®Google Scholar
• Li S, Wang Z, Huang J, Fan J, Du H, Liu L, Che G. Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: does the ‘obesity paradox’ really exist? Eur J Cardiothorac Surg. 2017;51(5):817–28. doi: 10.1093/ejcts/ezw386.
   PubMed Web of Science ®Google Scholar
• Bagheri M, Speakman JR, Shemirani F, Djafarian K. Renal cell carcinoma survival and body mass index: a dose-response meta-analysis reveals another potential paradox within a paradox. Int J Obes (Lond). 2016;40(12):1817–22. doi: 10.1038/ijo.2016.171.
   PubMed Web of Science ®Google Scholar
• Sanchez A, Furberg H, Kuo FS, Vuong L, Ged Y, Patil S, Ostrovnaya I, Petruzella S, Reising A, Patel P, et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol. 2020;21(2):283–93. doi: 10.1016/S1470-2045(19)30797-1.
   PubMed Web of Science ®Google Scholar
• Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14. doi: 10.1093/annonc/mdu042.
   PubMed Web of Science ®Google Scholar
• Protani MM, Nagle CM, Webb PM. Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2012;5(7):901–10. doi: 10.1158/1940-6207.CAPR-12-0048.
   PubMed Web of Science ®Google Scholar
• Staehler M, Stöckle M, Christoph DC, Stenzl A, Potthoff K, Grimm MO, Klein D, Harde J, Brüning F, Goebell PJ, et al. Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: final results of the MARC-2 trial. Int J Cancer. 2021;148(7):1685–94. doi: 10.1002/ijc.33349.
   PubMed Web of Science ®Google Scholar
• Santoni M, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, et al. Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: a new prognostic factor? Diagnostics. 2021;11(1):138. doi: 10.3390/diagnostics11010138.
   Web of Science ®Google Scholar
• Albiges L, Flechon A, Chevreau C, Topart D, Gravis G, Oudard S, Tourani JM, Geoffrois L, Meriaux E, Thiery-Vuillemin A, et al. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL Early Access Program. Eur J Cancer. 2021;142:102–11. (doi: 10.1016/j.ejca.2020.09.030.
   PubMed Web of Science ®Google Scholar
• Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, Adami HO, Lee JE, Lee HM. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2013;132(3):625–34. doi: 10.1002/ijc.27639.
   PubMed Web of Science ®Google Scholar
• Zhang GM, Zhu Y, Dong DH, Gu WJ, Zhang HL, Sun LJ, Ye DW. Clinical outcome of advanced and metastatic renal cell carcinoma treated with targeted therapy: is there a difference between young and old patients? Onco Targets Ther. 2014;7:2043–52. doi: 10.2147/OTT.S70012.
   PubMed Web of Science ®Google Scholar
• Steffens S, Grunwald V, Ringe KI, Seidel C, Eggers H, Schrader M, Wacker F, Kuczyk MA, Schrader AJ. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist. 2011;16(11):1565–71. doi: 10.1634/theoncologist.2011-0213.
   PubMed Web of Science ®Google Scholar
• Ladoire S, Bonnetain F, Gauthier M, Zanetta S, Petit JM, Guiu S, Kermarrec I, Mourey E, Michel F, Krause D, et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist. 2011;16(1):71–81. doi: 10.1634/theoncologist.2010-0227.
   PubMed Web of Science ®Google Scholar
• Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. and Group P-P Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. doi: 10.1136/bmj.g7647.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Response to: practical methods for incorporating summary time-to-event data into meta. Authors’ Reply. Trials. 2013;14:391.
   Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8(16):16. doi: 10.1186/1745-6215-8-16.
   PubMedGoogle Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. doi: 10.1007/s10654-010-9491-z.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, Bias Methods G, and Cochrane Statistical Methods G The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. doi: 10.1136/bmj.d5928.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P, Haas N, Doehn C, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Lim HY, et al. Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 PROTECT trial. Eur Urol. 2021;79(3):334–8. doi: 10.1016/j.eururo.2020.12.029.
   PubMed Web of Science ®Google Scholar
• Bergerot PG, Bergerot CD, Philip EJ, Meza L, Dizman N, Hsu J, Pal SK. Targeted therapy and immunotherapy: effect of body mass index on clinical outcomes in patients diagnosed with metastatic renal cell carcinoma. KCA. 2019;3(1):63–70. doi: 10.3233/KCA-180047.
   Google Scholar
• Kim MS, Chung HS, Hwang EC, Jung SI, Kwon DD, Hwang JE, Bae WK, Park JY, Jeong CW, Kwak C, et al. Efficacy of first-line targeted therapy in real-world Korean patients with metastatic renal cell carcinoma: focus on sunitinib and pazopanib. J Korean Med Sci. 2018;33(51):e325. doi: 10.3346/jkms.2018.33.e325.
   PubMed Web of Science ®Google Scholar
• Auclin E, Bourillon C, De Maio E, By MA, Seddik S, Fournier L, Auvray M, Dautruche A, Vano YA, Thibault C, et al. Prediction of everolimus toxicity and prognostic value of skeletal muscle index in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2017;15(3):350–5. doi: 10.1016/j.clgc.2017.01.022.
   PubMed Web of Science ®Google Scholar
• Albiges L, Hakimi AA, Xie WL, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol. 2016;34(30):3655–63. doi: 10.1200/JCO.2016.66.7311.
   PubMed Web of Science ®Google Scholar
• Pantano F, Santoni M, Procopio G, Rizzo M, Iacovelli R, Porta C, Conti A, Lugini A, Milella M, Galli L, et al. The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker? PLoS One. 2015;10(4):e0120427. doi: 10.1371/journal.pone.0120427.
   PubMed Web of Science ®Google Scholar
• Gu WJ, Zhu Y, Wang HK, Zhang HL, Shi GH, Liu XH, Ye DW. Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: a retrospective case series. PLoS One. 2015;10(2):e0118022. doi: 10.1371/journal.pone.0118022.
   PubMed Web of Science ®Google Scholar
• Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, et al. Active smokingmay negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treatedwith sunitinib. Oncologist. 2014;19(1):51–60. doi: 10.1634/theoncologist.2012-0335.
   PubMedGoogle Scholar
• Shen N, Fu P, Cui B, Bu CY, Bi JW. Associations between body mass index and the risk of mortality from lung cancer: a dose-response PRISMA-compliant meta-analysis of prospective cohort studies. Medicine (Baltimore). 2017;96(34):e7721. doi: 10.1097/MD.0000000000007721.
   PubMed Web of Science ®Google Scholar
• Wu S, Liu J, Wang X, Li M, Gan Y, Tang Y. Association of obesity and overweight with overall survival in colorectal cancer patients: a meta-analysis of 29 studies. Cancer Causes Control. 2014;25(11):1489–502. doi: 10.1007/s10552-014-0450-y.
   PubMed Web of Science ®Google Scholar
• Bae HS, Kim HJ, Hong JH, Lee JK, Lee NW, Song JY. Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis. J Ovarian Res. 2014;7:41. doi: 10.1186/1757-2215-7-41.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A, Varricchio A, et al. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(3):e213520. doi: 10.1001/jamanetworkopen.2021.3520.
   PubMed Web of Science ®Google Scholar
• Chen H, Wang D, Zhong Q, Tao Y, Zhou Y, Shi Y. Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunol Immunother. 2020;69(12):2413–24. doi: 10.1007/s00262-020-02680-y.
   PubMed Web of Science ®Google Scholar
• An Y, Wu Z, Wang N, Yang Z, Li Y, Xu B, Sun M. Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Transl Med. 2020;18(1):235. doi: 10.1186/s12967-020-02404-x.
   PubMed Web of Science ®Google Scholar
• Takemura K, Yonekura S, Downey LE, Evangelopoulos D, Heng DYC. Impact of body mass index on survival outcomes of patients with metastatic renal cell carcinoma in the immuno-oncology era: a systematic review and meta-analysis. Eur Urol Open Sci. 2022;39:62–71. doi: 10.1016/j.euros.2022.03.002.
   PubMedGoogle Scholar
• Köstek O, Yılmaz E, Hacıoğlu MB, Demircan NC, Gökyer A, Uzunoğlu S, Tunçbilek N, Çiçin İ, Erdoğan B. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer. Cancer Chemother Pharmacol. 2019;83(4):735–42. doi: 10.1007/s00280-019-03779-5.
   PubMed Web of Science ®Google Scholar
• Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28(6):1054–60. doi: 10.1200/JCO.2009.24.9730.
   PubMed Web of Science ®Google Scholar
• Hainer V, Aldhoon HI. Obesity paradox does exist. Diabetes Care. 2013;36 Suppl 2(Suppl 2):S276–S81. (doi: 10.2337/dcS13-2023.
   PubMedGoogle Scholar
• Oreopoulos A, Kalantar-Zadeh K, Sharma AM, Fonarow GC. The obesity paradox in the elderly: potential mechanisms and clinical implications. Clin Geriatr Med. 2009;25(4):643–59, viii. doi: 10.1016/j.cger.2009.07.005.
   PubMed Web of Science ®Google Scholar
• Strulov Shachar S, Williams GR. The obesity paradox in cancer-moving beyond BMI. Cancer Epidemiol Biomarkers Prev. 2017;26(1):13–6. doi: 10.1158/1055-9965.EPI-16-0439.
   PubMed Web of Science ®Google Scholar
• Bundhun PK, Li N, Chen MH. Does an obesity paradox really exist after cardiovascular intervention?: a systematic review and meta-analysis of randomized controlled trials and observational studies. Medicine (Baltimore). 2015;94(44):e1910. doi: 10.1097/MD.0000000000001910.
   PubMed Web of Science ®Google Scholar
• Andersen KK, Olsen TS. The obesity paradox in stroke: lower mortality and lower risk of readmission for recurrent stroke in obese stroke patients. Int J Stroke. 2015;10(1):99–104. doi: 10.1111/ijs.12016.
   PubMed Web of Science ®Google Scholar
• Park JS, Koo KC, Chung DY, Kim SI, Kim J, Oh CK, Kim TN, Kang SK, Park JW, Yoon YE, et al. Visceral adiposity as a significant predictor of sunitinib-induced dose-limiting toxicities and survival in patients with metastatic clear cell renal cell carcinoma. Cancers (Basel). 2020;12(12):3602. doi: 10.3390/cancers12123602.
   Web of Science ®Google Scholar
• Aleixo GFP, Shachar SS, Nyrop KA, Muss HB, Malpica L, Williams GR. Myosteatosis and prognosis in cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;145:102839. doi: 10.1016/j.critrevonc.2019.102839.
   PubMed Web of Science ®Google Scholar
• Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67. doi: 10.1016/j.ejca.2015.12.030.
   PubMed Web of Science ®Google Scholar
• Rinninella E, Cintoni M, Raoul P, Ponziani FR, Pompili M, Pozzo C, Strippoli A, Bria E, Tortora G, Gasbarrini A, et al. Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. Intern Emerg Med. 2021;16(5):1341–56. doi: 10.1007/s11739-020-02589-5.
   PubMed Web of Science ®Google Scholar
• Taki Y, Sato S, Nakatani E, Higashizono K, Nagai E, Nishida M, Watanabe M, Ohata K, Kanemoto H, Oba N. Preoperative skeletal muscle index and visceral-to-subcutaneous fat area ratio are associated with long-term outcomes of elderly gastric cancer patients after gastrectomy. Langenbecks Arch Surg. 2021;406(2):463–71. doi: 10.1007/s00423-021-02092-1.
   PubMed Web of Science ®Google Scholar
• Imai Y, Lee SW, Kawai M, Tashiro K, Kawashima S, Tanaka R, Honda K, Matsuo K, Uchiyama K. Visceral fat area is a better indicator of surgical outcomes after laparoscopic gastrectomy for cancer than the body mass index: a propensity score-matched analysis. Surg Endosc. 2022;36(5):3285–97. doi: 10.1007/s00464-021-08642-4.
   PubMed Web of Science ®Google Scholar
• Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21(8):1594–8. doi: 10.1093/annonc/mdp605.
   PubMed Web of Science ®Google Scholar